The National Comprehensive Cancer Network has released a free resource to help patients with acute myeloid leukemia and their families become better informed in treatment decision-making. READ MORE
Research presented at the 2018 BMT Tandem Meetings showed that potential role of immune checkpoint inhibitors in the post-transplant setting for patients with relapsed or large B-cell lymphomas.
A study to be presented at the BMT Tandem Meetings found no difference in OS for patients aged 55-64 years compared with those aged 65 years and older with non-Hodgkin lymphoma who underwent alloHCT.
Survival outcomes may be worse for patients with ALL living in intermediate and high socioeconomically deprived areas as well as for those treated in hospitals with lower volumes of patients.
Which first-line treatment strategy was shown to be safe and effective in older patients with newly diagnosed Ph-negative ALL?